CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionDebt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.71%
Annual Rate
KRW 228.00Paid annual
Payout Ratio
17.2%Sustainable
Payback Period
21.2 yr
Last Ex-Dividend
Mar 30, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
487.64BKRW351.38M · vs all stocks (USD)
Revenue (TTM)
122.44BKRW88.23M · vs all stocks (USD)
Profit Margin
-41.02%vs Medical Devices peers
Beta
0.6230xvs all stocks
52-Week Change
-15.68%vs all stocks
Market Capitalization
487.64BKRW351.38M · vs all stocks (USD)
Enterprise Value
135.59BKRW97.70M · vs all stocks (USD)
Price to Sales (TTM)
4.04xvs Medical Devices peers
Price to Book (MRQ)
0.3159xvs Medical Devices peers
Enterprise to Revenue
1.11xvs Medical Devices peers
Enterprise to EBITDA
4.83xvs Medical Devices peers
Gross Margin
58.93%vs Medical Devices peers
Profit Margin
-41.02%vs Medical Devices peers
Operating Margin
19.51%vs Medical Devices peers
Return on Assets (TTM)
0.70%vs Medical Devices peers
Return on Equity (TTM)
-3.18%vs Medical Devices peers
Revenue (TTM)
122.44BKRW88.23M · vs all stocks (USD)
Revenue per Share (TTM)
1.21KKRWUpdated Aug 20, 2026Quarterly Revenue Growth
14.50%vs Medical Devices peers
Gross Profit (TTM)
69.60BKRW50.15M · vs all stocks (USD)
EBITDA (TTM)
28.05BKRW20.21M · vs all stocks (USD)
Net Income (TTM)
-50.23BKRW-36.19M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
925.40%vs Medical Devices peers
Operating Cash Flow (TTM)
23.88BKRW17.21M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
13.72BKRW9.89M · vs all stocks (USD)
Trailing Annual Dividend Rate
228.00KRWUpdated Aug 20, 2026Trailing Annual Dividend Yield
4.71%vs all stocks
Payout Ratio
17.23%vs Medical Devices peers
Revenue
118.32BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
52.56BKRWFY2025 · Dec 31, 2025Gross Profit
65.77BKRWFY2025 · Dec 31, 2025Operating Income
16.81BKRW12.11M · vs all stocks (USD)
Pre-tax Income
-87.57BKRWFY2025 · Dec 31, 2025Income Tax Expense
-70.26MKRWFY2025 · Dec 31, 2025Net Income
-87.50BKRWFY2025 · Dec 31, 2025EBIT
-87.28BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-78.25BKRWFY2025 · Dec 31, 2025Research & Development
16.84BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
11.79BKRWFY2025 · Dec 31, 2025Other Operating Expenses
1.17BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
14.70BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
287.12MKRWFY2025 · Dec 31, 2025EPS (Basic)
-865.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-865.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
101.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
101.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-87.50BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-104.72BKRWFY2025 · Dec 31, 2025Free Cash Flow
-105.15BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
17.87BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-87.50BKRWFY2025 · Dec 31, 2025Stock-based Compensation
264.80MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-14.42BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.67BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
7.61BKRWFY2025 · Dec 31, 2025Capital Expenditures
-436.49MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-158.52MKRWFY2025 · Dec 31, 2025Net Acquisitions
-52.38BKRWFY2025 · Dec 31, 2025Purchase of Investments
-449.41BKRWFY2025 · Dec 31, 2025Sale of Investments
424.37BKRWFY2025 · Dec 31, 2025Other Investing Activity
550.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-77.85BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-5.00BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-20.27BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-25.27BKRWFY2025 · Dec 31, 2025Shares Outstanding
100.75MSharesUpdated Aug 20, 2026Float Shares
13.38MSharesUpdated Aug 20, 2026% Held by Insiders
80.23%vs all stocks
% Held by Institutions
5.98%vs all stocks
Total Cash (MRQ)
363.35BKRW261.82M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.61KKRWUpdated Aug 20, 2026Total Debt (MRQ)
3.33BKRW2.40M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0022xvs Medical Devices peers
Current Ratio (MRQ)
10.15xvs Medical Devices peers
Book Value per Share (MRQ)
15.32KKRWUpdated Aug 20, 2026Total Assets
1.56TKRW1.12B · vs all stocks (USD)
Total Current Assets
406.82BKRWFY2025 · Dec 31, 2025Total Liabilities
44.65BKRWFY2025 · Dec 31, 2025Total Non-current Assets
1.15TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
31.53BKRWFY2025 · Dec 31, 2025Total Current Liabilities
13.12BKRWFY2025 · Dec 31, 2025Cash Equivalents
17.87BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
17.87BKRWFY2025 · Dec 31, 2025Other Short-term Investments
321.94BKRWFY2025 · Dec 31, 2025Accounts Receivable
31.46BKRWFY2025 · Dec 31, 2025Inventory
27.69BKRWFY2025 · Dec 31, 2025Accounts Payable
4.16BKRWFY2025 · Dec 31, 2025Short-term Debt
1.49BKRWFY2025 · Dec 31, 2025Other Current Liabilities
87.72MKRWFY2025 · Dec 31, 2025Long-term Debt
2.16BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
330.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
51.03BKRWFY2025 · Dec 31, 2025Retained Earnings
1.34TKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
1.51TKRW1.09B · vs all stocks (USD)
Treasury Stock
8.11BKRWFY2025 · Dec 31, 202552-Week Low
4.05KKRWUpdated Aug 20, 202652-Week High
6.32KKRWUpdated Aug 20, 202652-Week Change
-15.68%vs all stocks
Beta
0.6230xvs all stocks
50-Day MA
4.64KKRWUpdated Aug 20, 2026200-Day MA
5.20KKRWUpdated Aug 20, 2026Avg 10-Day Volume
77.83KSharesUpdated Aug 20, 2026Avg 30-Day Volume
83.91KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-865.00KRWUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How is this stock valued?
Inverted P/B With Liquidity And Equity Ratio
It trades below book value, with current assets ample and the balance sheet equity-funded.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)Notable
Debt-to-equity: 0.00Industry median: 0.11Industry P5: 0.00Peers compared: 102
Price-to-book is 0.32×, lower than 95% of its Medical Devices peers (median 2.69×)Notable
Price-to-book: 0.32Industry median: 2.69Industry P5: 0.66Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.59Profit Margin: -0.41
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cellectis S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationInverted P/B With Liquidity And Equity Ratio
Wuhan Easydiagnosis Biomedicine Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationInverted P/B With Liquidity And Equity Ratio
Hyundai Futurenet Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationInverted P/B With Liquidity And Equity Ratio